MedDataX Logo

Transplant of Epithelium Conjunctival Human Autologous Cultivated ex Vivo in Amniotic Membrane for the Treatment of Symblepharon

NCT ID: NCT00799526

Last Updated: 2008-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface in patients with symblepharon.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

10 patients will be included from 16 to 90 years with presence of symblepharon, what have been already subjected to proceedings of reconstruction of the ocular surface without success and to present conjunctival healthy. In the place of biopsy and after the surgery of the patient one will be applied ointment with antibiotic and corticoid to minimize the inflammatory effects. The fragments will be transported even it laboratory of Molecular Biology of the advanced Centre of Ocular Surface where it will be prosecuted by means of technique sterile under laminating flow. The conjunctival epithelias cells will be put on the amniotic membrane compartments of the plate of culture where the appropriate ways will be added. After 2 weeks the membranes colonized with epithelium conjunctival they will be subjected to the coloration and the cloth will be used for the surgery of reconstruction of the ocular surface. It will be carried out first us an evaluation ophthalmologic complete weekly, 2 months and then fortnightly up to the sixth month post-operative.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symblepharon

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ex Vivo Conjunctival Epithelial Cell Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ex Vivo Transplantation

Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation

Group Type EXPERIMENTAL

Autologous Ex Vivo Conjunctival for Symblepharon Transplantation

Intervention Type PROCEDURE

Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.

Ex Vivo Conjunctival for Symblepharon Transplantation

Intervention Type PROCEDURE

The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous Ex Vivo Conjunctival for Symblepharon Transplantation

Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.

Intervention Type PROCEDURE

Ex Vivo Conjunctival for Symblepharon Transplantation

The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with ocular surface disorders, e.g. symblepharon
* Indications for surgery will be the presence of ocular surface symptoms in the affected eye, loss of visual acuity from visual axis obscuration or irregular astigmatism, or cosmesis.
* Only one eye of a patient will be eligible for study entry.
* Patients who are adult males and females who are aged 16 or older, and are considered mentally sound
* Patients who are willing to undergo long-term follow-up, as outlined in this protocol
* Patients who have signed an informed consent form that has been approved by the SNEC Ethics Committee.

Exclusion Criteria

* Patients less than 16 years of age
* Patients who are incapable, either by law or of mental state, of giving consent in their own right
* Patients who are either unable or unwilling to keep scheduled appointments and adhere to the other aspects of the protocol
* Patients who are pregnant or breastfeeding
* Patients with a history of drug allergy
* Patients who have received an investigational drug within 28 days preceding surgery
* Patients with intraocular pressure over 21 mmHg or history of ocular hypertension or glaucoma
* Patients who are documented to be steroid responders
Minimum Eligible Age

16 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal University of São Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

UNIFESP, SAO PAULO, SP, BRAZIL

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1075/08

Identifier Type: -

Identifier Source: org_study_id